• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2、SARS-CoV 和 MERS-CoV 的病毒载量动态、病毒脱落持续时间和传染性:系统评价和荟萃分析。

SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis.

机构信息

Division of Infection and Global Health Research, School of Medicine, University of St Andrews, Fife, UK.

NHS Lothian Infection Service, Regional Infectious Diseases Unit, Western General Hospital, Edinburgh, UK.

出版信息

Lancet Microbe. 2021 Jan;2(1):e13-e22. doi: 10.1016/S2666-5247(20)30172-5. Epub 2020 Nov 19.

DOI:10.1016/S2666-5247(20)30172-5
PMID:33521734
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7837230/
Abstract

BACKGROUND

Viral load kinetics and duration of viral shedding are important determinants for disease transmission. We aimed to characterise viral load dynamics, duration of viral RNA shedding, and viable virus shedding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in various body fluids, and to compare SARS-CoV-2, SARS-CoV, and Middle East respiratory syndrome coronavirus (MERS-CoV) viral dynamics.

METHODS

In this systematic review and meta-analysis, we searched databases, including MEDLINE, Embase, Europe PubMed Central, , and , and the grey literature, for research articles published between Jan 1, 2003, and June 6, 2020. We included case series (with five or more participants), cohort studies, and randomised controlled trials that reported SARS-CoV-2, SARS-CoV, or MERS-CoV infection, and reported viral load kinetics, duration of viral shedding, or viable virus. Two authors independently extracted data from published studies, or contacted authors to request data, and assessed study quality and risk of bias using the Joanna Briggs Institute Critical Appraisal Checklist tools. We calculated the mean duration of viral shedding and 95% CIs for every study included and applied the random-effects model to estimate a pooled effect size. We used a weighted meta-regression with an unrestricted maximum likelihood model to assess the effect of potential moderators on the pooled effect size. This study is registered with PROSPERO, CRD42020181914.

FINDINGS

79 studies (5340 individuals) on SARS-CoV-2, eight studies (1858 individuals) on SARS-CoV, and 11 studies (799 individuals) on MERS-CoV were included. Mean duration of SARS-CoV-2 RNA shedding was 17·0 days (95% CI 15·5-18·6; 43 studies, 3229 individuals) in upper respiratory tract, 14·6 days (9·3-20·0; seven studies, 260 individuals) in lower respiratory tract, 17·2 days (14·4-20·1; 13 studies, 586 individuals) in stool, and 16·6 days (3·6-29·7; two studies, 108 individuals) in serum samples. Maximum shedding duration was 83 days in the upper respiratory tract, 59 days in the lower respiratory tract, 126 days in stools, and 60 days in serum. Pooled mean SARS-CoV-2 shedding duration was positively associated with age (slope 0·304 [95% CI 0·115-0·493]; p=0·0016). No study detected live virus beyond day 9 of illness, despite persistently high viral loads, which were inferred from cycle threshold values. SARS-CoV-2 viral load in the upper respiratory tract appeared to peak in the first week of illness, whereas that of SARS-CoV peaked at days 10-14 and that of MERS-CoV peaked at days 7-10.

INTERPRETATION

Although SARS-CoV-2 RNA shedding in respiratory and stool samples can be prolonged, duration of viable virus is relatively short-lived. SARS-CoV-2 titres in the upper respiratory tract peak in the first week of illness. Early case finding and isolation, and public education on the spectrum of illness and period of infectiousness are key to the effective containment of SARS-CoV-2.

FUNDING

None.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc5e/7837230/fc909c7dde60/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc5e/7837230/c5b126758929/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc5e/7837230/348fcc95d6cc/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc5e/7837230/b347f8dacdbe/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc5e/7837230/fc909c7dde60/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc5e/7837230/c5b126758929/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc5e/7837230/348fcc95d6cc/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc5e/7837230/b347f8dacdbe/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc5e/7837230/fc909c7dde60/gr4.jpg
摘要

背景

病毒载量动力学和病毒脱落持续时间是疾病传播的重要决定因素。我们旨在描述严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)在各种体液中的病毒载量动力学、病毒 RNA 脱落持续时间和活病毒脱落,并比较 SARS-CoV-2、SARS-CoV 和中东呼吸综合征冠状病毒(MERS-CoV)的病毒动力学。

方法

在这项系统评价和荟萃分析中,我们检索了数据库,包括 MEDLINE、Embase、欧洲 PubMed 中心、 和 ,以及灰色文献,以检索 2003 年 1 月 1 日至 2020 年 6 月 6 日期间发表的研究文章。我们纳入了病例系列(有 5 名或以上参与者)、队列研究和随机对照试验,这些研究报告了 SARS-CoV-2、SARS-CoV 或 MERS-CoV 感染,并报告了病毒载量动力学、病毒脱落持续时间或活病毒。两名作者独立从已发表的研究中提取数据,或联系作者请求数据,并使用 Joanna Briggs 研究所的批判性评估清单工具评估研究质量和偏倚风险。我们计算了每个研究的病毒脱落平均持续时间和 95%置信区间,并应用随机效应模型来估计汇总效应大小。我们使用无限制最大似然模型的加权荟萃回归来评估潜在调节因素对汇总效应大小的影响。这项研究在 PROSPERO 注册,CRD42020181914。

发现

纳入了 79 项关于 SARS-CoV-2(5340 人)、8 项关于 SARS-CoV(1858 人)和 11 项关于 MERS-CoV(799 人)的研究。上呼吸道 SARS-CoV-2 RNA 脱落的平均持续时间为 17.0 天(95%CI 15.5-18.6;43 项研究,3229 人),下呼吸道为 14.6 天(9.3-20.0;7 项研究,260 人),粪便为 17.2 天(14.4-20.1;13 项研究,586 人),血清为 16.6 天(3.6-29.7;2 项研究,108 人)。上呼吸道最大脱落持续时间为 83 天,下呼吸道为 59 天,粪便为 126 天,血清为 60 天。SARS-CoV-2 脱落的平均持续时间与年龄呈正相关(斜率 0.304 [95%CI 0.115-0.493];p=0.0016)。尽管病毒载量持续很高,但没有研究检测到发病后第 9 天以上的活病毒,这是从循环阈值推断出来的。上呼吸道 SARS-CoV-2 病毒载量似乎在发病的第一周达到峰值,而 SARS-CoV 的病毒载量在第 10-14 天达到峰值,MERS-CoV 的病毒载量在第 7-10 天达到峰值。

解释

尽管呼吸道和粪便样本中的 SARS-CoV-2 RNA 脱落可能会延长,但活病毒的持续时间相对较短。上呼吸道 SARS-CoV-2 病毒载量在发病的第一周达到峰值。早期发现病例并进行隔离,以及对疾病谱和传染性期进行公众教育,是有效控制 SARS-CoV-2 的关键。

资助

无。

相似文献

1
SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis.SARS-CoV-2、SARS-CoV 和 MERS-CoV 的病毒载量动态、病毒脱落持续时间和传染性:系统评价和荟萃分析。
Lancet Microbe. 2021 Jan;2(1):e13-e22. doi: 10.1016/S2666-5247(20)30172-5. Epub 2020 Nov 19.
2
Defining within-host SARS-CoV-2 RNA viral load kinetics during acute COVID-19 infection within different respiratory compartments and their respective associations with host infectiousness: a protocol for a systematic review and meta-analysis.定义急性新冠肺炎感染期间不同呼吸道腔室内的宿主内严重急性呼吸综合征冠状病毒2(SARS-CoV-2)RNA病毒载量动力学及其与宿主传染性的各自关联:一项系统评价和荟萃分析方案
BMJ Open. 2024 Dec 2;14(12):e085127. doi: 10.1136/bmjopen-2024-085127.
3
Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic.与严重冠状病毒感染相关的精神和神经精神症状表现:一项系统综述和荟萃分析,并与新冠疫情进行比较
Lancet Psychiatry. 2020 Jul;7(7):611-627. doi: 10.1016/S2215-0366(20)30203-0. Epub 2020 May 18.
4
Duration of viable virus shedding and polymerase chain reaction positivity of the SARS-CoV-2 Omicron variant in the upper respiratory tract: a systematic review and meta-analysis.奥密克戎变异株在上呼吸道存活病毒和聚合酶链反应阳性的持续时间:系统评价和荟萃分析。
Int J Infect Dis. 2023 Apr;129:228-235. doi: 10.1016/j.ijid.2023.02.011. Epub 2023 Feb 18.
5
Heterogeneity in transmissibility and shedding SARS-CoV-2 via droplets and aerosols.飞沫和气溶胶传播 SARS-CoV-2 的传染性和脱落的异质性。
Elife. 2021 Apr 16;10:e65774. doi: 10.7554/eLife.65774.
6
Prolonged Shedding of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at High Viral Loads Among Hospitalized Immunocompromised Persons Living With Human Immunodeficiency Virus (HIV), South Africa.南非免疫功能低下的人类免疫缺陷病毒(HIV)感染者住院患者中高病毒载量下严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的长时间脱落。
Clin Infect Dis. 2022 Aug 24;75(1):e144-e156. doi: 10.1093/cid/ciac077.
7
Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort study.SARS-CoV-2 传染性的发病和窗口期,以及与症状发作的时间相关性:一项前瞻性、纵向、社区队列研究。
Lancet Respir Med. 2022 Nov;10(11):1061-1073. doi: 10.1016/S2213-2600(22)00226-0. Epub 2022 Aug 18.
8
Prevalence of Gastrointestinal Symptoms and Fecal Viral Shedding in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis.2019 年冠状病毒病患者的胃肠道症状和粪便病毒脱落的流行情况:系统评价和荟萃分析。
JAMA Netw Open. 2020 Jun 1;3(6):e2011335. doi: 10.1001/jamanetworkopen.2020.11335.
9
Differences of Severe Acute Respiratory Syndrome Coronavirus 2 Shedding Duration in Sputum and Nasopharyngeal Swab Specimens Among Adult Inpatients With Coronavirus Disease 2019.新型冠状病毒肺炎成年住院患者痰液与鼻咽拭子标本中 2019 年冠状病毒脱落持续时间的差异。
Chest. 2020 Nov;158(5):1876-1884. doi: 10.1016/j.chest.2020.06.015. Epub 2020 Jun 20.
10
Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity.SARS-CoV-2 G614 感染(武汉株)患者新冠病毒载量随症状出现和严重程度的变化轨迹。
JAMA Netw Open. 2022 Jan 4;5(1):e2142796. doi: 10.1001/jamanetworkopen.2021.42796.

引用本文的文献

1
Evaluating COVID-19 vaccination policy in Québec (Canada) using a data-driven dynamic transmission model.使用数据驱动的动态传播模型评估加拿大魁北克省的新冠疫苗接种政策。
PLoS Comput Biol. 2025 Aug 25;21(8):e1013207. doi: 10.1371/journal.pcbi.1013207. eCollection 2025 Aug.
2
The efficacy and safety of inhaled peptide YKYY017 for COVID-19 patients with mild illness: a phase 2 randomized controlled trial.吸入式肽YKYY017用于轻症COVID-19患者的疗效与安全性:一项2期随机对照试验。
Nat Commun. 2025 Aug 7;16(1):7272. doi: 10.1038/s41467-025-62214-x.
3
Personalized risk score prediction and testing policy adaptations of a COVID-19 population-based contact tracing network.

本文引用的文献

1
Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on the Inflammatory Response and Viral Clearance in COVID-19 Patients.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂对COVID-19患者炎症反应和病毒清除的影响
Front Cardiovasc Med. 2021 Aug 19;8:710946. doi: 10.3389/fcvm.2021.710946. eCollection 2021.
2
Early Viral Clearance and Antibody Kinetics of COVID-19 Among Asymptomatic Carriers.无症状携带者中 COVID-19 的早期病毒清除及抗体动力学
Front Med (Lausanne). 2021 Mar 15;8:595773. doi: 10.3389/fmed.2021.595773. eCollection 2021.
3
Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered: A single-center, retrospective, observational study.
基于人群的COVID-19接触者追踪网络的个性化风险评分预测及检测策略调整
Epidemiol Infect. 2025 Jul 24;153:e90. doi: 10.1017/S0950268825100319.
4
Hippo pathway and NLRP3-driven NETosis in macrophages: Mechanisms of viral pneumoniaaggravation.巨噬细胞中河马通路和NLRP3驱动的中性粒细胞胞外陷阱形成:病毒性肺炎加重的机制
Cell Death Discov. 2025 Jul 14;11(1):323. doi: 10.1038/s41420-025-02556-z.
5
Host-Virus Interface in Persistent SARS-CoV-2 Infections: Viral Characteristic Evolution and Gene Expression Profiling Analysis.持续性新冠病毒感染中的宿主-病毒界面:病毒特征演变与基因表达谱分析
Int J Mol Sci. 2025 Jun 27;26(13):6221. doi: 10.3390/ijms26136221.
6
Identifying bellwether sewershed sites for sustainable disease surveillance in Bengaluru, India: a longitudinal study.确定印度班加罗尔可持续疾病监测的风向标排水流域站点:一项纵向研究
Lancet Reg Health Southeast Asia. 2025 Jun 17;39:100619. doi: 10.1016/j.lansea.2025.100619. eCollection 2025 Aug.
7
Immune transcriptomic analysis on COVID-19 patients with varying clinical presentations identifies severity markers.对具有不同临床表现的新冠肺炎患者进行免疫转录组分析,确定了疾病严重程度标志物。
Sci Rep. 2025 Jul 2;15(1):23416. doi: 10.1038/s41598-025-04837-0.
8
Role of ACE1, ACE2, and CCR5-Δ32 Polymorphisms in the Transmission of SARS-CoV-2 to Intimate Contacts.ACE1、ACE2和CCR5-Δ32基因多态性在严重急性呼吸综合征冠状病毒2(SARS-CoV-2)向密切接触者传播中的作用
Biology (Basel). 2025 May 22;14(6):587. doi: 10.3390/biology14060587.
9
Clinical effectiveness, safety, and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomized Phase III trial.口服法匹拉韦治疗新冠肺炎的临床有效性、安全性及病毒诱变性:一项基于社区的开放标签随机 III 期试验结果
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0005425. doi: 10.1128/aac.00054-25. Epub 2025 Jun 24.
10
Severe acute respiratory syndrome coronavirus-2 shedding in exhaled material: a systematic review.呼出物中严重急性呼吸综合征冠状病毒2的脱落:一项系统评价
Epidemiol Infect. 2025 Jun 20;153:e75. doi: 10.1017/S0950268825100174.
中国东北七个城市 55 例 COVID-19 患者的治愈医疗:一项单中心、回顾性、观察性研究。
Medicine (Baltimore). 2021 Jan 15;100(2):e23923. doi: 10.1097/MD.0000000000023923.
4
SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus.在新冠肺炎患者血液制品中检测到的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)RNA与传染性病毒无关。
Wellcome Open Res. 2020 Oct 12;5:181. doi: 10.12688/wellcomeopenres.16002.2. eCollection 2020.
5
Duration of SARS-CoV-2 detection in Israel Defense Forces soldiers with mild COVID-19.以色列国防军轻症新冠病毒肺炎士兵中新冠病毒2检测的持续时间。
J Med Virol. 2021 Feb;93(2):608-610. doi: 10.1002/jmv.26374. Epub 2020 Aug 13.
6
Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2.用于检测严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的唾液或鼻咽拭子样本
N Engl J Med. 2020 Sep 24;383(13):1283-1286. doi: 10.1056/NEJMc2016359. Epub 2020 Aug 28.
7
Validation of Predictors of Disease Severity and Outcomes in COVID-19 Patients: A Descriptive and Retrospective Study.验证 COVID-19 患者疾病严重程度和结局的预测因子:一项描述性和回顾性研究。
Med. 2020 Dec 18;1(1):128-138.e3. doi: 10.1016/j.medj.2020.05.002. Epub 2020 May 19.
8
Comparative study on virus shedding patterns in nasopharyngeal and fecal specimens of COVID-19 patients.新型冠状病毒肺炎患者鼻咽和粪便标本病毒脱落模式的比较研究
Sci China Life Sci. 2021 Mar;64(3):486-488. doi: 10.1007/s11427-020-1783-9. Epub 2020 Aug 5.
9
Impact of delays on effectiveness of contact tracing strategies for COVID-19: a modelling study.新冠病毒接触者追踪策略有效性延迟的影响:建模研究。
Lancet Public Health. 2020 Aug;5(8):e452-e459. doi: 10.1016/S2468-2667(20)30157-2. Epub 2020 Jul 16.
10
Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19.新型冠状病毒肺炎患者病毒 RNA 脱落持续时间与临床特征和治疗方案的相关性。
Int J Infect Dis. 2020 Sep;98:252-260. doi: 10.1016/j.ijid.2020.06.091. Epub 2020 Jun 30.